Regeneron’s Disclaimer of Aflibercept Formulation Patent Causes PTAB Denial of Institution …

On March 15, 2022, the Patent Trial and Appeal Board (PTAB) denied institution of post-grant review (PGR) proceedings initiated by Celltrion Inc.